Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental condition that causes hyperactivity and impulsivity in children and adults. If left untreated ...
In A Nutshell • A brain stimulation device cleared by the FDA in 2019 failed to beat placebo in a rigorous 150-participant ...
Launches of Tuzulby® methylphenidate prolonged-release chewable tablets and Paxneury® guanfacine prolonged-release tablets, also in 5mg, 6mg, and 7mg strengths Two differentiated treatments exemplify ...
Stimulant drugs and another medication – atomoxetine – appear to be the best treatment for managing symptoms of ADHD, a study suggests. Monique Wüstenhagen/dpa Talking therapy and brain stimulation ...
SHANGHAI, Jan. 8, 2026 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced that China's National Medical Products Administration (NMPA) has approved the New Drug ...
ROCKVILLE, Md. - Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a biopharmaceutical company specializing in CNS diseases with an impressive 89% gross profit margin, has announced the FDA approval of a ...
This article was reviewed by Lynn Marie Morski, MD, JD. Key Takeaways: ADHD and menopause symptoms can overlap, and one ...
For years, people thought that attention deficit hyperactivity disorder (ADHD) was a problem that only kids had. It was ...
SHANGHAI, Jan. 6, 2026 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced that China's National Medical Products Administration (NMPA) has approved the New Drug ...